CardioExchange Archive

October 6th, 2010

The Skinny on Drug-Eluting Stents (DES)

Richard A. Lange, MD, MBA

(“All we want are the facts, ma’am.” –Joe Friday, Dragnet) Having trouble keeping up with DES and the recent stent studies? Want a brief tutorial? To learn the top six things every cardiologist should know about DES, read on… 1. What they do. DES are superior to both bare-metal stents and angioplasty in reducing the incidence […]

---

September 24th, 2010

Xience V Stent Still Strong at 2 Years

Larry Husten, PHD

Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES). Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure — defined […]

---

September 20th, 2010

What Does Gregg Stone Most Want to See at TCT This Year?

Gregg W Stone, MD

CardioExchange asked Gregg Stone, Director of the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting, what he thinks will be the three most important trials or topics presented at this year’s conference. The most important and impactful trial is undoubtedly the PARTNER trial, which is a large randomized trial of transcatheter aortic valve implantation compared to medical therapy […]

---

August 30th, 2010

Study Finds African-Americans at Increased Risk for Stent Thrombosis

Larry Husten, PHD

African-Americans are nearly three times more likely than other races to develop stent thrombosis after receiving a drug-eluting stent, according to a new study appearing in Circulation. Ron Waksman and colleagues analyzed data from a large, single-center registry of 7,236 patients who received a DES and found that African-American race was the single strongest predictor […]

---